仑伐替尼联合信迪利单抗对晚期肝癌患者肿瘤标志物水平及生存情况的影响  

The Effect of Lenvatinib Combined with Xindilimab on Tumor Marker Levels and Survival in Patients with Advanced Liver Cancer

作　　者：周国辉 Zhou Guohui(Affiliated Hospital of Putian University,Putian Fujian 351100,China)

机构地区：[1]莆田学院附属医院,福建莆田351100

出　　处：《哈尔滨医药》2025年第2期4-7,共4页Harbin Medical Journal

摘　　要：目的探讨仑伐替尼联合信迪利单抗对晚期肝癌患者肿瘤标志物水平及生存情况的影响。方法回顾性收集96例晚期肝癌患者资料,按不同治疗方案分为对照组(48例)、研究组(48例);对照组予仑伐替尼治疗,研究组予仑伐替尼联合信迪利单抗治疗,均至少治疗3个周期;统计并对比两组的治疗效果、肿瘤标志物水平、肝功能指标、生存质量、不良反应及生存情况。结果研究组疾病控制率较对照组高(P<0.05);研究组治疗3个周期,甲胎蛋白(AFP)、癌胚抗原(CEA)、异常凝血酶原(PIVKA-Ⅱ)、糖类抗原(CA199)、总胆红素(TBIL)、谷草转氨酶(AST)、丙氨酸氨基转移酶(ALT)水平较对照组低;研究组治疗3个周期癌症患者生命质量测定量表(EORTC QLQ-C30)各维度评分较对照组高(P<0.05);研究组不良反应与对照组对比,差异无统计学意义(P>0.05);研究组存活率较对照组高(P<0.05)。结论仑伐替尼联合信迪利单抗治疗晚期肝癌患者效果较好,可降低肿瘤标志物水平,减轻肝功能损伤,改善生存质量,提高生存率,且安全性好。Objective To investigate the effects of lenvatinib combined with sintilimab on tumor marker levels and survival in patients with advanced liver cancer.Method A retrospective collection of data was conducted on 96 patients with advanced liver cancer.They were divided into a control group(48 cases)and a study group(48 cases)according to different treatment plans;The control group was treated with lenvatinib,while the study group was treated with lenvatinib combined with sildenafil monoclonal antibody for at least 3 cycles;Compare and analyze the treatment efficacy,tumor marker levels,liver function indicators,quality of life,adverse reactions,and survival status between the two groups.The disease control rate of the research group(70.83%)was higher than that of the control group(41.67%)(P<0.05);The research group had lower levels of alpha fetoprotein(AFP),carcinoembryonic antigen(CEA),abnormal prothrombin(PIVKA II),carbohydrate antigen(CA199),total bilirubin(TBIL),aspartate aminotransferase(AST),and alanine aminotransferase(ALT)compared to the control group after three cycles of treatment;The study group had higher scores in all dimensions of the EORTC QLQ-C30 quality of life assessment scale for cancer patients treated for three cycles compared to the control group(P<0.05);There was no statistically significant difference in adverse reactions between the study group(14.58%)and the control group(10.42%)(P>0.05);The survival rate of the study group was higher than that of the control group,and the median survival time was longer than that of group A(P<0.05).Conclusion The combination of lenvatinib and xindilimab is effective in the treatment of advanced liver cancer patients,reducing tumor marker levels,alleviating liver function damage,improving quality of life,and increasing survival rate,with good safety.

关 键 词：晚期肝癌 仑伐替尼 信迪利单抗 肿瘤标志物 生存情况 

分 类 号：R735.7[医药卫生—肿瘤]